The estimated Net Worth of Bio Ventures 2014, L.P.Mpm ... is at least $8.44 million dollars as of 23 June 2020. Bio Mpm owns over 250,000 units of Repare Therapeutics stock worth over $8,440,599 and over the last 4 years Bio sold RPTX stock worth over $0.
Bio has made over 1 trades of the Repare Therapeutics stock since 2020, according to the Form 4 filled with the SEC. Most recently Bio bought 250,000 units of RPTX stock worth $5,000,000 on 23 June 2020.
The largest trade Bio's ever made was buying 250,000 units of Repare Therapeutics stock on 23 June 2020 worth over $5,000,000. On average, Bio trades about 250,000 units every 0 days since 2020. As of 23 June 2020 Bio still owns at least 3,003,772 units of Repare Therapeutics stock.
You can see the complete history of Bio Mpm stock trades at the bottom of the page.
Over the last 4 years, insiders at Repare Therapeutics have traded over $111,956,457 worth of Repare Therapeutics stock and bought 8,747,790 units worth $117,182,784 . The most active insiders traders include Partners L P/Ilbiotechnolog..., David P Bonita et Group, Llc Green Jeremy Red.... On average, Repare Therapeutics executives and independent directors trade stock every 15 days with the average trade being worth of $446,135. The most recent stock trade was executed by Lloyd Mitchell Segal on 28 March 2024, trading 5,141 units of RPTX stock currently worth $23,751.
Repare Therapeutics Inc., a precision oncology company, discovers and develops novel therapeutics by using its synthetic lethality approach in Canada and the United States. The company uses its SNIPRx, a proprietary, genome-wide, and CRISPR-enabled platform to systematically discover and develop highly targeted cancer therapies focused on genomic instability, including DNA damage repair. Its lead product candidate is RP-3500, an oral small-molecule inhibitor for the treatment of solid tumors with specific DNA damage repair-related genomic alterations. It is also developing RP-6306, a proprietary drug discovery program for tumors with genetic alterations characterized by CCNE1 amplification; and Polymerase Theta program, a SL target associated with BRCA mutations and other genomic alterations. Repare Therapeutics Inc. was incorporated in 2016 and is headquartered in Montréal, Canada.
Repare Therapeutics executives and other stock owners filed with the SEC include: